Fulcrum Therapeutics (FULC) Return on Sales (2020 - 2024)
Historic Return on Sales for Fulcrum Therapeutics (FULC) over the last 6 years, with Q1 2025 value amounting to 0.21%.
- Fulcrum Therapeutics' Return on Sales rose 398300.0% to 0.21% in Q1 2025 from the same period last year, while for Mar 2025 it was 0.21%, marking a year-over-year increase of 398300.0%. This contributed to the annual value of 0.12% for FY2024, which is 345800.0% up from last year.
- According to the latest figures from Q1 2025, Fulcrum Therapeutics' Return on Sales is 0.21%, which was up 398300.0% from 0.12% recorded in Q4 2024.
- Fulcrum Therapeutics' 5-year Return on Sales high stood at 0.69% for Q2 2024, and its period low was 84.0% during Q1 2023.
- For the 5-year period, Fulcrum Therapeutics' Return on Sales averaged around 18.43%, with its median value being 10.0% (2022).
- In the last 5 years, Fulcrum Therapeutics' Return on Sales crashed by -739900bps in 2023 and then surged by 443800bps in 2024.
- Fulcrum Therapeutics' Return on Sales (Quarter) stood at 4.64% in 2021, then plummeted by -722bps to 38.15% in 2022, then rose by 26bps to 28.42% in 2023, then surged by 100bps to 0.12% in 2024, then surged by 276bps to 0.21% in 2025.
- Its Return on Sales stands at 0.21% for Q1 2025, versus 0.12% for Q4 2024 and 0.22% for Q3 2024.